Most Popular
|
Research Trends
|
| Next-Generation Humanized Models Construction Technology: TurboKnockout® |
| May 31, 2024 |
| There are typically two techniques used for the genetic modification of mice: embryonic steam (ES) targeting and CRISPR. Read More > |
| The Value of hTTR & hTTR V50M Humanized Mice in Developing Therapies for Transthyretin Amyloidosis |
| May 24, 2024 |
| A leading RNAi therapy company, Alnylam, recently disclosed its performance results for 2023, which revealed that its two siRNA drugs targeting transthyretin (TTR) for the treatment of amyloidosis, patisiran and vutrisiran, collectively generated sales exceeding $913 million. Read More > |
|
Research Trends
|
| Can B6-hIGHMBP2 Humanized Mice Offer a Breakthrough for Spinal and Peroneal Muscular Atrophy Research? |
| May 17, 2024 |
| On January 23, 2024, Vanda Pharmaceuticals (VNDA) announced that its antisense nucleotide (ASO) drug VCA-894A targeting the IGHMBP2 gene has officially received FDA's Investigational New Drug (IND) approval. Read More > |
|
Research Trends
|
| Humanized Model for Therapeutic Targets of Parkinson's Disease Dementia: B6-hSNCA Mice |
| May 11, 2024 |
| In this issue, we introduce the genetically humanized SNCA model - B6-hSNCA mouse (product number: C001427), providing a next-generation humanized mouse model for drug discovery for the key therapeutic target of Parkinson's Disease (PD) & Dementia with Lewy Bodies (DLB). Read More > |
|
Research Trends
|
| Psoriasis Targeted Drug Evaluation Model—B6-hIL-17A Mice |
| Apr 26, 2024 |
| In this issue, we introduce the Psoriasis Targeted Drug Evaluation Model—B6-hIL-17A Humanized Mice, which provides an improved platform for preclinical disease modeling of psoriasis treatments for effective and efficient clinical translation. Read More > |
|
Research Trends
|
| Spinocerebellar Ataxia Type III (SCA3) Research Model—B6-hATXN3 Mice |
| Apr 19, 2024 |
| This issue introduces the Spinocerebellar Ataxia Type III (SCA3) research mouse model—B6-hATXN3 mice (Product Number: C001398). Moreover, B6-hATXN3 mice exclusively express the human gene - unlike the common B6-TG(ATXN3-84Q) mice, which express both the human ATXN3 gene and the mouse Atxn3 gene. Read More > |
|
Research Trends
|
| Amyotrophic Lateral Sclerosis (ALS) TDP-43 Proteinopathy Research Model - B6-hTARDBP Mice |
| Apr 16, 2024 |
| This issue introduces the TDP-43 proteinopathy research model - B6-hTARDBP mice (Product Number: C001418). In amyotrophic lateral sclerosis (ALS), pathological abnormalities of TDP-43 protein are almost universally present, regardless of whether the TARDBP gene is mutated. Read More > |
|
Research Trends
|
| Suitable Preclinical Atherosclerosis Research Model: B6J-Apoe Knockout Mice |
| Apr 03, 2024 |
| In this issue, we introduce the B6J-Apoe knockout (KO) mouse model for atherosclerosis research. Atherosclerosis, a specific type of arteriosclerosis, is a chronic immune-metabolic inflammatory disease that causes the buildup of fats, cholesterol and other substances on the artery walls. Read More > |
|
Breaking News
Newsletter
|
| Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery |
| Mar 28, 2024 |
| Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. Read More > |
|
Research Trends
|
| Hemophilia B Disease Model - F9 Knockout Mice |
| Mar 21, 2024 |
| In this issue, we introduce the Hemophilia B disease mouse model - F9 Knockout (KO) Mice. Hemophilia is a group of hereditary bleeding disorders characterized by a deficiency in clotting factor activity, leading to prolonged clotting time and a risk of bleeding even after minor injuries. Read More > |
